CXCR4 and acute myeloid leukemia: The engineered vMIP‐II‐TAT‐I peptide demonstrated superior cellular uptake, exhibiting a 7.2‐fold higher MFI in CXCR4‐positive AML cells compared to non‐targeted controls.